Drug discovery

Lilly, Acrux receive FDA approval for Axiron

November 24, 2010
 IBJ Staff and Bloomberg News
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
More

Lilly scores series of small victories

November 17, 2010
J.K. Wall
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
More

Study: Arthritis drug co-developed by Lilly shows promise

November 12, 2010
 IBJ Staff and Bloomberg News
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
More

Moody's downgrades long-term ratings for Eli Lilly

November 9, 2010
Associated Press
Moody's Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
More

Lilly makes $300M deal for Philadelphia drug company

November 8, 2010
J.K. Wall
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
More

Seeking growth, Lilly dumps Singapore for China

November 3, 2010
J.K. Wall
After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker's presence in the world's fastest-growing pharmaceutical market.
More

Lilly to open diabetes research center in China

November 2, 2010
 IBJ Staff
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
More

Eli Lilly will have to beat odds to meet drug-rollout goals

October 30, 2010
J.K. Wall
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
More

Analysts: Lilly setbacks might spur shopping spree

October 22, 2010
Bloomberg News
CEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
More

Lilly suspends clinical trials after diabetes treatment fails

October 20, 2010
Bloomberg News
Eli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
More

UPDATE: Lilly, others see stock slide after drug rejection

October 20, 2010
Bloomberg News
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
More

FDA demands more tests on new Lilly diabetes drug

October 19, 2010
J.K. Wall
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
More

Lilly to close drug discovery center in Singapore

October 18, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150 million plan to expand it.
More

Consultants: Pharma industry facing huge changes

October 6, 2010
J.K. Wall
Heitzman_WatchVideoTo date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
More

CEO says Lilly still not interested in huge acquisitions

September 7, 2010
 IBJ Staff and Bloomberg News
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
More

Lilly wins ban of generic Strattera pending appeal

August 31, 2010
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until the court rules on a judge's decision invalidating a patent on the medicine.
More

Endocyte's $86M IPO plan a boon for Indiana, investors

August 28, 2010
Greg Andrews
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital, Clarian Health Ventures and the Indiana Future Fund.
More

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Diabetes research pioneer Kirtley dies at 96

August 25, 2010
Associated Press
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a groundbreaking Eli Lilly researcher.
More

Pearl IRB first firm in state to pre-screen clinical drug trialsRestricted Content

August 21, 2010
Chris O'Malley
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
More

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Cancer drug developer Endocyte files for IPO

August 18, 2010
Scott Olson
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet to be determined.
More

Lilly Alzheimer's drug prospect only the latest to fail

August 18, 2010
Bloomberg News
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid- to late-stage testing since 2003.
More

Lilly among bidders for Denmark company, source says

July 30, 2010
Bloomberg News
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said. Ascendis may choose a final bidder by early September.
More

New rules raise stakes for Lilly drug

July 21, 2010
J.K. Wall
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses of the disease.
More
Page  << 1 2 3 4 5 6 7 8 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT